<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612273</url>
  </required_header>
  <id_info>
    <org_study_id>4-2011-0018</org_study_id>
    <nct_id>NCT01612273</nct_id>
  </id_info>
  <brief_title>The Effect of Triflusal on Peripheral Microcirculation Dysfunction</brief_title>
  <official_title>The Effect of Triflusal on Peripheral Microcirculation Dysfunction: A Double-Blind, Randomized, Controlled, Crossover Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy of triflusal in patients with symptomatic peripheral microcirculation
      dysfunction. Triflusal is a salicylate compound approved in several countries as
      antithrombotic agent and it additionally has vasodilatory effect. The hypothesis is to
      explore if there is a improvement of peripheral microcirculation by triflusal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome - The amount of blood flow measured by finger doppler ultrasonography. The improvement of subjective symptom measured by questionaire.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Comparison of the PSV (peak systolic velocity) and EDV (end diastolic velocity) measured by finger doppler ultrasonography between disgren and aspirin groups after 6 weeks treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Vasospastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Disgren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triflusal</intervention_name>
    <description>Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.</description>
    <arm_group_label>Disgren</arm_group_label>
    <other_name>Disgren®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>Astrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 40 and 70 years of age

          -  Diagnosed vasospastic syndrome with nailfold capillaroscopy (Fingertip is subjected to
             carbon dioxide at -15°C for 60 seconds. People found to have a blood-flow standstill
             of at least 12s in one or more capillaries were defined as having vasospasticity)

          -  More than seven points in 10-question interview provided by Nagashima et al.

          -  Written informed consent

        Exclusion Criteria:

          -  Prior documented diabetes

          -  Overt peripheral artery disease

          -  Pregnant or nursing

          -  bleeding tendency

          -  Any contraindication of antiplatelet agent

          -  Thrombocytopenia (platelet &lt; 100,000mm3)

          -  Chronic liver disease (ALT &gt; 100 IU/L or AST &gt; 100 IU/L) or renal dysfunction
             (creatinine &gt; 4.0 mg/dl)

          -  Patients who can not stop to take aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>March 4, 2014</last_update_submitted>
  <last_update_submitted_qc>March 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasospastic syndrome</keyword>
  <keyword>Vascular dysregulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Triflusal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

